Abstract:AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO The development of tumor metastasis comprises a complex cascade of events that involves multiple intercellular interactions. Cellular and molecular pathways that regulate platelet activation, blood coagulation, and inflammation are critical players in tumor growth and metastasis. In particular, thrombin and platelet activating factor (PAF), through the activity of their specific G-protein-coupled receptors, act as putative mediators of tumor growth, angiogenesis, and metastasis. Surprisingly little is known about their mechanism(s) of action. Here, we demonstrate a novel signaling axis whereby the activation of Protease-Activated Receptor 1 (PAR1) regulates melanoma cell adhesion to endothelial cells, diapedesis, and lung metastasis via PAF receptor-mediated expression of the Melanoma Cell Adhesion Molecule MCAM/MUC18, thus linking the inflammatory microenvironment with melanoma metastasis. Indeed, in A375SM and C8161-c9 metastatic melanoma cells, silencing of PAR1 with small hairpin RNA resulted in downregulation of expression of PAFR and a decrease in PAF production. Silencing of either PAR1 or PAFR expression abrogated expression of MCAM/MUC18, a critical marker of homo- and heterotypic adhesion in melanoma. Overexpression of PAFR led to restoration of MCAM/MUC18 expression in PAR1shRNA cells, suggesting that PAFR acts downstream of PAR1. PAR1 silencing resulted in a loss of MCAM/MUC18 promoter activity, which was associated with the decreased binding and activity of CREB. Silencing of PAR1 or CREB also induced stronger in vivo binding of EGR1 and inhibition of Sp1 binding to MCAM/MUC18 promoter. Furthermore, silencing of PAR1 resulted in dramatic inhibition of melanoma cell adhesion and migration over the Human Dermal Microendothelial Cells (HDMECs), as well as a decreased retention of melanoma cells in lungs of nude mice after tail vein injection. Silencing MCAM/MUC18 produced similar non-metastatic phenotype. However, while melanoma cell adhesion to HDMECs, diapedesis and retention in lungs were rescued upon overexpression of PAFR in PAR1shRNA cells, only adhesion was rescued by overexpression of MCAM/MUC18. This suggested that in addition to MCAM/MUC18, other downstream targets of PAR1/PAFR signaling axis were required for metastatic dissemination of melanoma cells. Indeed, RT-PCR analysis in PAR1shRNA and PAFRshRNA cells revealed that PAR1 and PAFR modulate expression of the MMP-2 and VEGF, which are known to increase tumor cell invasiveness, vascular permeability, and metastatic dissemination into lungs. Overall, our results suggest that PAR1 and PAFR are critical targets for intervention with melanoma metastasis. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1109.

Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA.

Intravenous Delivery of Sirna Targeting Cd47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis

Therapeutic Silence of Pleiotrophin by Targeted Delivery of Sirna and Its Effect on the Inhibition of Tumor Growth and Metastasis

Study on the Role of Protease-Activated Receptor 1 in Promoting B16F10 Metastasis in Vitro and in Vivo

Poly(N-vinylpyrrolidone)- block-Poly(dimethylsiloxane)- block-Poly(N-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast Cancers

Rnai Targeting Urokinase-Type Plasminogen Activator Receptor Inhibits Metastasis And Progression Of Oral Squamous Cell Carcinoma In Vivo

Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.

Effective Suppression of the Kirsten Rat Sarcoma Viral Oncogene in Pancreatic Tumor Cells Via Targeted Small Interfering RNA Delivery Using Nanoparticles

Dually Regulating the Proliferation and the Immune Microenvironment of Melanomaviananoparticle-Delivered Sirna Targeting Onco-Immunologic CD155

Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles.

Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model

Abstract #1109: the Signaling Pathway PAR1-PAFR-MCAM/MUC18 Links Inflammation with Melanoma Metastasis

Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma

Dual Targeted Immunotherapy Via in Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells

Dual Receptor-Specific Peptides Modified Liposomes As VEGF Sirna Vector for Tumor-Targeting Therapy

Anti-Metastatic Effects on Melanoma via Intravenous Administration of Anti-NF-κB siRNA Complexed with Functional Peptide-Modified Nano-Micelles

Sirna Packaged with Neutral Cytidinyl/Cationic/PEG Lipids for Enhanced Antitumor Efficiency and Safety in Vitro and in Vivo.

Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer Sirna Therapy in Vivo.

Polymer-lipid Hybrid Nanovesicle-Enabled Combination of Immunogenic Chemotherapy and RNAi-mediated PD-L1 Knockdown Elicits Antitumor Immunity Against Melanoma.

Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas

Biomineralized Polydopamine Nanoparticle-Based Sodium Alginate Hydrogels for Delivery of Anti-serine/Threonine Protein Kinase B-Rapidly Accelerated Fibrosarcoma siRNA for Metastatic Melanoma Therapy